Target intelligence / Profile preview

Cyclin Y (CCNY)

Target: CCNY
Molecular classification: Cyclin family protein, Cell cycle regulator, Regulatory subunit for cyclin-dependent kinases (CDKs, specifically CDK14/PFTK1 and CDK16/PCTAIRE1)

Overview

Cyclin Y (CCNY) is a highly conserved member of the cyclin family, serving as an essential regulatory subunit for atypical cyclin-dependent kinases. It most commonly forms complexes with CDK14 (PFTK1) and CDK16 (PCTAIRE1), mediating key transitions in the cell cycle, controlling cell division, signal transduction (notably Wnt signaling), and cytoskeletal dynamics. CCNY is implicated in diverse biological processes such as embryonic development, neuronal function, immune regulation, and autophagy. Aberrant CCNY expression has been linked to cancer progression, increased cell migration (including metastasis in lung cancer), autoimmune diseases, and neurological disorders. CCNY is emerging as both a candidate diagnostic biomarker and a potential therapeutic target in oncology and inflammation.

Other names: Cyclin YCCNY

Mechanism of action

Modulation of CDK activity through complex formation (primarily with CDK14/PFTK1 and CDK16/PCTAIRE1), affecting cell cycle, cytoskeleton dynamics, and signaling pathways

Biological functions

Cell cycle regulationCell proliferationSignal transduction: Wnt signaling pathway (via LRP6 phosphorylation)Cell migration and invasion (cytoskeletal remodeling)Immune regulationSpermatogenesisNeural developmentAutophagy

Disease associations

Cancer (especially lung, kidney, and laryngeal cancers; high expression linked to proliferation and metastasis)Inflammatory bowel disease, autoimmune diseases (genetic susceptibility)Neurodegenerative diseases, epilepsy (altered neuronal functions)

Safety considerations

Targeting cell cycle regulators like CCNY may pose risks of myelosuppression or toxicity affecting proliferative tissues; off-target effects are possible but not yet documented due to lack of clinical inhibitors

Biomarkers

Increased CCNY expression as a potential biomarker for several cancers, especially as a predictive marker of tumor progression and prognosis

Beyond the preview

Go deeper on Cyclin Y (CCNY).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclin Y (CCNY).

Explore the full profile